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The innovative technology introduced by Timmerman 
and colleagues3 deserves praise, keeping in mind that this 
new arrow in the DBS quiver does not fulﬁ ll completely 
the needs and expectations of this area of research. 
Advanced electrode designs, including segmented and 
high spatial resolution leads, are needed to improve our 
capacity to control and direct current spread further. 
Novel stimulation models, such as closed-loop and 
coordinated reset neuromodulation, might allow us to 
retune abnormal patterns of neural synchronisation. In 
the end, the future of DBS as a clinical and translational 
science will depend on our ability to unravel its 
mechanisms of action. Only when we better understand 
and control—versus empirically guess—the eﬀ ects of 
DBS on the CNS will the revolutionary power of this 
technology fully exert its therapeutic promise.
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Assisted nutrition: a diﬃ  cult decision in patients with 
amyotrophic lateral sclerosis
Management of patients with amyotrophic lateral 
sclerosis is a diﬃ  cult task for the clinician. Diﬃ  culties 
start when making the correct diagnosis, which is 
often a protracted process because symptoms can start 
slowly, and the neurologist might refrain from making 
a diagnosis of amyotrophic lateral sclerosis for a long 
time owing to its poor prognosis. Once the diagnosis 
is established, besides traditional neurological care, 
palliative care skills are needed, which often are not in 
the forefront of neurological thinking. Amyotrophic 
lateral sclerosis aﬀ ects not only neurological functions 
such as those of the motor system, but also survival 
functions such as breathing and eating. Finally, the 
clinician also has to resolve the issue of how patients 
will die and be cared for during the terminal phase.1,2
A diagnosis of amyotrophic lateral sclerosis is of 
course also diﬃ  cult for the patients themselves and their 
families. Especially late in the disease, the fear of choking 
and the uncertainty of what will come next are most 
pressing. Where legally available, many patients opt 
for active euthanasia, showing the high psychological 
burden on patients and relatives.3,4 In such circumstances, 
clinical decisions about respiration and nutrition are 
highly emotionally charged. In-depth insight into the 
patient’s view of amyotrophic lateral sclerosis is best 
provided by qualitative studies,5,6 and for patients and 
clinicians to be able to make joint meaningful clinical 
decisions scientiﬁ c data are desperately needed.
One new small piece in the mosaic of clinical decision 
making in amyotrophic lateral sclerosis is presented 
in The Lancet Neurology by the ProGas Study Group,7 
who followed up a large cohort of 330 patients with 
amyotrophic lateral sclerosis in the UK who underwent 
gastrostomy. The study, although not randomised, 
shows that, in the decision to do a gastrostomy, 
clinicians can choose among percutaneous endoscopic 
gastrostomy, radiologically inserted gastrostomy, or 
per-oral image-guided gastrostomy: the method used 
does not seem to aﬀ ect the disease course, shown by the 
primary endpoint of mortality within 30 days (ﬁ ve [3%] 
of 163 patients died after percutaneous endoscopic 
gastrostomy, four [3%] of 121 after radiologically 
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Multiple system atrophy in the USA: another piece in 
the jigsaw
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Multiple system atrophy is a devastating orphan neuro-
degenerative disease1 that has seen an encouraging 
increase in translational research.2 Two large 
randomised controlled trials have been published since 
2014.3,4 Unfortunately, both failed to show a signiﬁ cant 
eﬀ ect on disease progression. Two academically driven 
prospective observational studies laid the foundation 
for the statistical assumptions of future interventional 
inserted gastrostomy, and three [7%] of 43 after per-
oral image-guided gastrostomy; p=0·46), and by similar 
numbers of complications in each group. However, 
percutaneous endoscopic gastrostomy in sertion was 
the most burdensome for the patient. 
The results of the study also show that, in most 
instances, artiﬁ cial nutrition does not achieve the 
outcomes that clinicians would expect: little weight gain, 
if any, was achieved and the quality of life of patients was 
not really changed. The authors suggest that if artiﬁ cial 
nutrition is considered, gastrostomy should be done 
early. They further suggest not waiting for weight loss of 
10% from diagnosis, as is currently recommended,8 but 
rather a weight loss of 5%. Other studies have argued that 
gastrostomy is safe even in patients with low forced vital 
capacity, but the procedure still carries risks.9 
Clinicians should speak about this decision with 
patients and their families as early as possible during 
the disease course. However, for this clinical discussion 
we need more than just technical data; we have to 
ask whether we do any good for patients by placing 
a gastrostomy. When is it really medically indicated? 
The study by the ProGas Study Group7 shows only little 
eﬀ ect, but  the study had no control group and does not 
show what happened to the patients who did not receive 
gastrostomy. Additionally, the investigators did not 
assess whether placement of gastrostomy has beneﬁ cial 
eﬀ ects later in the disease course by making it easier for 
patients to receive drugs for symptom control when 
they can no longer swallow, and preventing parenteral 
administration of these drugs becoming necessary. It 
is also not clear, once artiﬁ cial nutrition is started, how 
diﬃ  cult it is to stop (leaving the gastrostomy in place) if 
no eﬀ ect has been shown—yet another ethically diﬃ  cult 
decision. How much is really gained in terms of life 
expectancy and quality of life by gastrostomy?10 A similar 
discussion is ongoing for patients with dementia.11
For all these questions, which are of high clinical and 
ethical relevance, we need many more clinical studies, 
be they qualitative or quantitative, prospective cohort 
studies such as ProGas7 or, even better, randomised 
controlled trials. Funders of amyotrophic lateral sclerosis 
research have to be urged to look, in addition to 
molecular studies, at these clinical questions, which are 
very relevant to patients and their families.
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